Clene Inc. (NASDAQ:CLNN) Given Consensus Rating of “Moderate Buy” by Brokerages

Clene Inc. (NASDAQ:CLNN) has earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $33.25.

CLNN has been the topic of several research reports. Roth Capital reissued a “buy” rating on shares of Clene in a report on Thursday, May 14th. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Clene in a report on Monday, May 4th. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Clene in a research report on Monday, May 4th. Finally, Weiss Ratings downgraded Clene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th.

Institutional Investors Weigh In On Clene

Institutional investors have recently added to or reduced their stakes in the stock. SymBiosis Capital Partners LLC purchased a new position in Clene in the fourth quarter valued at about $4,523,000. Scoggin Management LP lifted its position in shares of Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares during the last quarter. Ensign Peak Advisors Inc lifted its position in shares of Clene by 668.6% during the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after buying an additional 99,481 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Clene by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after buying an additional 6,090 shares in the last quarter. Finally, PEAK6 LLC bought a new stake in shares of Clene in the 4th quarter valued at about $294,000. Institutional investors own 23.28% of the company’s stock.

Clene Stock Performance

NASDAQ CLNN opened at $5.16 on Tuesday. The company has a market capitalization of $65.94 million, a price-to-earnings ratio of -1.61 and a beta of 0.96. The company’s 50-day simple moving average is $5.73 and its two-hundred day simple moving average is $5.66. Clene has a one year low of $3.50 and a one year high of $13.50.

Clene (NASDAQ:CLNN) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.05). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.05 million. Equities analysts expect that Clene will post -1.58 earnings per share for the current fiscal year.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).